Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
EV/EBITDA has expanded 2395.8% YoY to 21.1x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 10.15 | — | — | 76.71 | — | 1.27 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.79 | 5.16 | 9.30 | 6.33 | 5.33 | 0.94 | 4.09 | 3.63 | 3.14 | 2.65 | 1.69 | 2.15 | 3.55 |
| — | +451.1% | +127.7% | +74.7% | +69.8% | -64.7% | +141.2% | +68.8% | -11.6% | -34.6% | -59.1% | -48.1% | -17.7% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | 9.33 | — | — | — | — | 1.27 | — | — | — | 86.79 | — | — | — |
| — | — | — | — | — | -98.5% | — | — | — | — | — | — | — | |
| EV / EBITDA | 6.77 | 21.14 | — | 91.67 | — | 0.85 | — | — | — | 52.77 | 11.08 | — | — |
| — | +2395.8% | — | — | — | -98.4% | — | — | — | — | — | — | — | |
| EV / EBIT | 7.07 | 28.24 | — | 136.04 | — | 0.86 | — | — | — | — | — | — | — |
| — | +3187.9% | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
PTC Therapeutics, Inc.'s operating margin was 16.8% in Q1 2026, up 66.4 pp QoQ and down 65.7 pp YoY. The trailing four-quarter average of -12.7% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 13.6% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.9% | 85.5% | 90.1% | 45.1% | 93.6% | 98.9% | 92.4% | 94.5% | 91.7% | 93.0% | 65.4% | 95.2% | 94.0% |
| — | -13.6% | -2.4% | -52.3% | +2.1% | +6.4% | +41.3% | -0.7% | -2.5% | -0.6% | -30.1% | +1.7% | -0.1% | |
| Operating Margin | 49.5% | 16.8% | -49.6% | 1.4% | -19.5% | 82.5% | -76.2% | -27.7% | -21.5% | -21.6% | 1.0% | -60.1% | -98.0% |
| — | -79.6% | +34.9% | +105.2% | +9.3% | +481.4% | -7597.0% | +53.9% | +78.0% | +59.5% | +100.8% | -77.6% | -75.6% | |
| Net Margin | 39.4% | -1.0% | -82.0% | 7.5% | -36.3% | 73.7% | -30.9% | -54.2% | -53.1% | -43.6% | -50.7% | -67.6% | -93.0% |
| — | -101.4% | -165.2% | +113.9% | +31.8% | +269.1% | +39.1% | +19.9% | +42.9% | +30.9% | +50.3% | -34.4% | -1.2% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | 29.6% | -0.1% | -4.9% | 0.6% | -2.5% | 39.7% | -3.7% | -5.7% | -5.4% | -5.0% | -9.9% | -10.2% | -13.5% |
| — | -100.2% | -30.8% | +110.6% | +54.2% | +899.8% | +62.4% | +44.6% | +60.3% | +40.7% | +5.2% | -58.3% | -59.9% | |
| ROIC | — | — | — | — | — | — | -20.5% | — | — | — | 0.7% | — | — |
| — | — | — | — | — | — | -3104.3% | — | — | — | +102.1% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
PTC Therapeutics, Inc.'s Debt/EBITDA ratio is 6.4x — elevated, raising questions about debt serviceability. The current ratio has weakened 37.3% YoY to 2.44x, tightening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | 0.55 | 6.45 | — | 35.80 | — | 0.40 | — | — | — | 42.39 | 26.59 | — | — |
| — | +1517.0% | — | — | — | -99.1% | — | — | — | — | — | — | — | |
| Current Ratio | 2.35 | 2.44 | 2.35 | 2.32 | 3.62 | 3.89 | 2.35 | 2.10 | 2.23 | 2.03 | 2.02 | 1.10 | 1.24 |
| — | -37.3% | -0.1% | +10.5% | +62.6% | +91.3% | +16.3% | +91.1% | +79.9% | +46.5% | +18.3% | -10.8% | +1.1% | |
| Quick Ratio | 2.27 | 2.36 | 2.27 | 2.26 | 3.57 | 3.85 | 2.31 | 2.04 | 2.17 | 1.98 | 1.97 | 1.03 | 1.17 |
| — | -38.8% | -1.9% | +10.6% | +64.0% | +94.5% | +17.3% | +99.0% | +85.7% | +49.2% | +19.1% | -14.3% | -2.3% | |
| Interest Coverage | 5.58 | 0.94 | -1.52 | 0.29 | -1.34 | 28.27 | -1.31 | -1.36 | -0.97 | -1.07 | -2.55 | -4.92 | -7.07 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PTCT stock.
PTC Therapeutics, Inc.'s current P/E is 10.2x. The average P/E over the last 1 quarters is 76.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
PTC Therapeutics, Inc.'s current operating margin is 49.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking PTC Therapeutics, Inc.'s business trajectory between earnings reports.